Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805316 | 0.89 | SLC22A12 (0.45) | SLC22A12MTNR1BCYP3A4NOTUM | |
| SCHEMBL4807517 | 0.83 | SLC22A12 (0.48) | SLC22A12MTNR1BNOTUMFNTAFNTB | |
| SCHEMBL5364926 | 0.80 | CYP3A4 (0.54) | CYP3A4PARP1FNTAFNTBPGGT1B | |
| SCHEMBL4800114 | 0.80 | ICAM1 (0.36) | CYP3A4PARP1FNTAFNTBPGGT1B | |
| SCHEMBL4807235 | 0.79 | APOBEC3G (0.40) | MTNR1BCYP3A4PARP1FNTAFNTB | |
| SCHEMBL5373702 | 0.78 | PARP1 (0.45) | CYP3A4PARP1ADORA2AADORA1 | |
| SCHEMBL5364878 | 0.78 | PARP1 (0.43) | CYP3A4PARP1FNTAFNTBPGGT1B | |
| SCHEMBL5374033 | 0.78 | CYP3A4 (0.41) | CYP3A4PARP1FNTAFNTBPGGT1B | |
| SCHEMBL5373478 | 0.77 | CYP3A4 (0.38) | CYP3A4PARP1FNTAFNTBPGGT1B | |
| SCHEMBL4661620 | 0.77 | PARP1 (0.38) | CYP3A4PARP1FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608633-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-7348345-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348345-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | DUNN JAMES P | 2007-08-02 | — | — | US | disclosed |
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | DUNN JAMES P | 2007-08-02 | — | — | US | disclosed |
| US-7208509-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208509-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208509-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | RRM2, RRM2B, SAMHD1 | SLC22A12 2342/4885MTNR1B 4095/4885CYP3A4 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.